Eli Lilly and Co. on March 14 said the company’s experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32 percent compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease.
AMO Pharma, a British biopharmaceutical company, is targeting a pathway most often associated with cancer to treat people with genetic encephalopathy (GE).
Dr. Ann McKee of Boston University studies the brains of deceased football players at the world’s largest brain bank, hoping to learn about the long-term impact of repeated head traumas for people ranging from professional athletes to victims of domestic abuse.
Quitting smoking is just about one of the hardest things you can do, but new research suggests there may be yet another serious reason to consider it. The new study in […]
“Shark Week,” the insanely popular week-long festival of flesh-ripping, terror-inducing finned creatures, is in full-swing on the Discovery Channel and no doubt will be just as popular as ever in […]
